FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Allergy topics
Autoimmune
Prophylactic
Ophthalmic
Autoimmune Disorder
Immune Disorder
Dermatitis
Staurosporin
Aspergillosis
Angioedema
Allergic Rhinitis
Food Allergy
Therapeutical
Bronchopulmonary
Staurosporine
Sudden Infant Death

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Allergy patents



      
           
This page is updated frequently with new Allergy-related patents. Subscribe to the Allergy RSS feed to automatically get the update: related Allergy RSS feeds.

Subscribe to updates on this page: Allergy RSS RSS

Date/App# patent app List of recent Allergy-related patents
04/17/14
20140107398
 Methods and devices for treating primary headache patent thumbnailnew patent Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
04/17/14
20140107397
 Methods and devices for treating primary headache patent thumbnailnew patent Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
04/17/14
20140107102
 Ocular allergy treatments patent thumbnailnew patent Ocular allergy treatments
Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.. .
04/10/14
20140100234
 Quinoline derivatives as pi3 kinase inhibitors patent thumbnailQuinoline derivatives as pi3 kinase inhibitors
Invented is a method of inhibiting the activity/function of pi3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives..
04/10/14
20140099331
 Zwitterionic immunomodulators for the teatment of asthma and allergy patent thumbnailZwitterionic immunomodulators for the teatment of asthma and allergy
Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain t regulatory (treg) cells and to exert immunosuppressive effects in vitro and in vivo..
04/03/14
20140093541
 Treatment for peanut allergy patent thumbnailTreatment for peanut allergy
The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years..
04/03/14
20140093509
 Screening method for the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4 patent thumbnailScreening method for the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4
The present invention relates specific activation of a regulatory t cell via a specific cd4 epitope and uses thereof, e.g. For the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction..
03/27/14
20140088172
 Rnai-mediated inhibition of histamine receptor h1-related conditions patent thumbnailRnai-mediated inhibition of histamine receptor h1-related conditions
Rna interference is provided for inhibition of histamine receptor h1 mrna expression, in particular, for treating patients having an hrh1-related condition or at risk of developing an hrh1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.. .
03/20/14
20140081071
 Methods and devices for treating primary headache patent thumbnailMethods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
03/20/14
20140080730
 Method for predicting severity of allergic reaction patent thumbnailMethod for predicting severity of allergic reaction
The present invention provides methods for determining a likelihood of a degree of allergic reaction or a severity thereof using a threshold value rather than the binding activity number between the immunoglobulin of the subject and a test composition comprising a marker protein moiety of the allergy inducing material. In one particular embodiment of the invention, methods are provided for determining a likelihood of a degree of allergic reaction severity of a subject to peanuts using a threshold value of binding between immunoglobulin e (ige) of the subject and ara h 2 moiety and ara h 6 moiety..
02/27/14
20140056933
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and ige-mediated allergy (type i allergy), especially pollen allergy and house dust allergy..
02/27/14
20140056892
Vista-ig for treatment of autoimmune, allergic and inflammatory disorders
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig). The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions..
02/20/14
20140051677
Novel compound useful for the treatment of degenerative and inflammatory diseases
Novel pyrrazolopyridines according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prophylaxis and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .
02/20/14
20140050750
Vaccine peptide combinations against cat allergy
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides. .
02/13/14
20140044744
Novel hypoallergens
The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies.
02/06/14
20140038995
Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
02/06/14
20140037792
Isolated microorganism strains lactobacillus plantarum mcc1 dsm 23881 and lactobacillus gasseri mcc2 dsm 23882 and their use
The present invention relates to new microorganism strains l. Plantarum mcc1 dsm 23881 and l.
02/06/14
20140037761
Method for preventing or treating an allergic disease using extract from illicium verum
The present invention provides a method for preventing or treating an allergic disease, comprising administering to a subject a composition comprising an extract from illicium verum as an active ingredient. The extract from illicium verum of the present invention reduces the secretion amount of increased histamine by compound 48/80 and the production amount of the increased allergenic cytokines (tnf-α, il-4 and il-8) by pma and a23187.
02/06/14
20140037686
Lactobacillus paracasei ncc2461 (st11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny
The present invention provides a probiotic, lactobacillus paracasei ncc 2461, i.e. St11, for use by administration to expectant females and/or lactating mothers, and to their progeny for the reduction or prevention of the development of allergic immune responses in progeny.
02/06/14
20140037663
Hypoallergen
The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies.
02/06/14
20140037661
Wheat antigens and peptides for diagnosis of wheat induced hypersensitivity
The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and ige-mediated allergy.
02/06/14
20140037634
Regulatory t cell mediator proteins and uses thereof
In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.
02/06/14
20140037603
Nutritional compositions including branched chain fatty acids for improving gut barrier function
Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. Such medical conditions include infection, sepsis, malabsorption, allergy, inflammatory bowel disease, and diarrhea among others.
01/30/14
20140030376
Gluten-free ready-to-eat food composition
A gluten free, ready-to-eat food product is provided comprising millet and a flavoring. In some embodiments, the gluten-free food product may also be dairy-free and/or allergen free.
01/30/14
20140030218
Treatment and screening
A method of treating a patient having an autoimmune disease or a th1 polarising infection or a condition associated with inflammation other than asthma or allergy, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of interferon regulatory factor 5 (irf5).. .
01/23/14
20140023669
Use of a hypoallergenic cereal composition for inducing specific oral tolerance
A partial hydrolysate of cereal protein for use in inducing specific oral tolerance in a young mammal with allergy to said cereal protein, wherein the hydrolysate has a degree of hydrolysis between 9 and 18%, is disclosed.. .
01/23/14
20140023614
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
The present invention relates to substituted fused tricyclic compounds of formula (i) or (ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by jak activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity.
01/16/14
20140018908
Gene delivery stent using titanium oxide thin film coating, and method for fabricating same
The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells.
01/16/14
20140018534
Benzimidazole derivatives as pi3 kinase inhibitors
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kβ, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
01/16/14
20140018408
Oligonucleotides for treating inflammation and neoplastic cell proliferation
There is provided oligonucleotides directed against the ccr3 receptor and the common beta sub-unit of il-3, il-5 and gmcsf receptors. The oligonucleotides are useful to inhibit general inflammation, including inflammation associated with asthma, copd, allergy, cystic fibrosis (cf), hypereosinophilia and neoplastic cell proliferation such as cancer..
01/09/14
20140010849
Peanut allergy treatment
The present invention provides compositions, systems, and methods for preventing and treating allergic reactions to peanut exposure. In certain embodiments, the present invention employs fusion proteins comprising a peanut allergen (or allergenic portion thereof), such as ara h2, and an fc protein (e.g., fcγ1 protein), or functional portion thereof..
01/02/14
20140004100
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
12/26/13
20130346074
Verification of extracted data
Facts are extracted from speech and recorded in a document using codings. Each coding represents an extracted fact and includes a code and a datum.
12/26/13
20130345209
Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
The present invention relates to the compound according to formula i, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound inhibits jak a family of tyrosine kinases, and more particularly jak1.
12/26/13
20130344042
Dietary management of celiac disease and food allergy
The present disclosure provides compositions and methods for dietary management of celiac disease and food allergy in a subject, such as a formula-fed infant, via enteral administration of an effective amount of at least one hydrolyzed protein and lactobacillus rhamnosus gg (lgg). The inventive nutritional compositions may contain a hydrolyzed protein component, a lipid component, a carbohydrate component, a vitamin component, a mineral component, and a prebiotic component in addition to a probiotic component, which comprises an effective amount of lgg..
12/19/13
20130336976
Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
12/12/13
20130331418
Methods for preventing flea allergy dermatitis in companion animals
Methods for reducing the incidence of flea allergy dermatitis (fad) in a companion animal are disclosed, the methods directed to inhibiting blood feeding by ectoparasites on a companion animal. The methods of the present invention involve administering a pesticide composition comprising cyphenothrin to a companion animal, specifically dogs and cats, in doses and proportions which are parasiticidally effective against a variety of ectoparasites, and in formulations which are convenient for topical application to the animal's skin, preferably localized over a small surface area.
11/28/13
20130316026
Xylitol-based anti-mucosal compositions and related methods and compositions
Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy medication or another anti-mucosal composition. In some embodiments, a nasal solution for alleviating an allergy condition may comprise an anti-mucosal composition in an amount effective for treating an allergy condition and at least one of xylitol and xylose in an amount effective for reducing nasal dryness caused by the anti-mucosal composition..
11/21/13
20130309270
Vaccines comprising bisphosphonate and methods of use thereof
The present invention demonstrates that bisphosphonates have an intrinsic adjuvant activity and directly stimulate b cell antibody secretion. Accordingly, the present invention provides vaccines comprising a bisphosphonate, methods for stimulating an immune response, enhancing the immunogenicicty of an immunogen, and methods of treating an infection, an autoimmune disease, an allergy, and/or a cancer using the same..
11/21/13
20130309261
Hypoallergenic polypeptides for the treatment of house dust mite allergy
The present invention relates to a polypeptide comprising the amino acid sequence as shown in seq id no:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines..
11/14/13
20130304184
Nickel-free stainless steel stent
A nickel-free stainless steel stent using a stainless steel which does not substantially contain ni in the stainless steel, has a metal allergy onset-preventing effect, and is excellent in terms of precision workability, strength, and ductility, is provided. The nickel-free stainless steel stent is characterized by using a stainless steel containing, as a chemical composition, from 15 to 30% by mass of cr, from 0.97 to 2% by mass of mo, and from 0.5 to 1% by mass of n, with the remainder being fe, and optionally containing inevitable impurities..
11/07/13
20130295200
Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions..
11/07/13
20130295146
Composition for improving membrane composition and functioning of cells
The health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery..
11/07/13
20130295123
Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy
The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, amb a 1.
11/07/13
20130292294
Allergy emergency kit
An allergy emergency kit (aek) for use in treating urgent allergic reactions in common areas for allergens to exist. Generally speaking, the kit comprises a container for securing allergy medicines, a customizable panel for fastening allergy medicine in an orderly fashion, at least anaphylaxis device fastened to the panel and positioned within the container, and an instruction sheet positioned within the container and listing urgent care details for victims of allergens.
10/31/13
20130290027
Electronic medical records system with active clinical guidelines and patient data
An active guidelines capability or component is linked to a computerized patient record system to integrate the use of clinical guidelines in the workflow of clinicians treating patients. Many healthcare entities maintain sets of clinical guidelines describing recommended treatment or analysis options for patients displaying sets of symptoms or for whom certain diagnoses have been made.
10/31/13
20130289440
Allergy testing device and method of testing for allergies
An allergy testing system comprises a skin test device having a grip portion for holding the device. One or more legs extend from the grip, and each leg is oriented to interact with a well containing a potential allergen.
10/31/13
20130289018
New use of staurosporine derivatives
This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a staurosporine derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.. .
10/24/13
20130281506
Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use
The present invention is directed to a stable formulation of a combination of ketorolac (non-steroidal anti-inflammatory drug) with olopatadine (anti-histaminic drug) intended for ophthalmic use. This pharmaceutical composition is used for treatment of ophthalmic diseases and conditions, particularly seasonal ocular surface allergy..
10/24/13
20130280302
Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) an extract of der p mite bodies, and b) an extract of der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) an extract of der p faecal particles, d) an extract of der f faecal particles, e) an extract of der f whole mite culture, f) an extract of an der p whole mite culture, and g) a combination of extracts c) to f).. .
10/10/13
20130267583
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
10/03/13
20130259884
Peptides
The application discloses peptides capable of preventing or treating fungal disease, including fungal allergy disease.. .
10/03/13
20130259735
Bio-co-cr-mo alloy with ion elution suppressed by structure control, and process for producing same
This invention provides a technique for rendering bio-toxicity such as allergy toxicity derived from ni trace impurity, i.e., nickel toxicity, which is unavoidably present in a bio-co—cr—mo alloy or an ni-free stainless steel alloy unharmful, characterized in that an element selected from the group consisting of the group 4, 5 and 13 elements of the periodic table, particularly an element selected from the group consisting of the group 4 elements of the periodic table, is added to the alloy composition. The additive element is preferably an element selected from the group consisting of zirconium and titanium, more preferably zirconium..
09/26/13
20130251666
Povidone iodine, a novel alternative preservative for ophthalmic compositions
The invention includes a preserved ophthalmic preparation comprising povidone-iodine (pvp-i) at a concentration sufficient to preserve the ophthalmic preparation, and at least one member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial compound, an anti-allergy compound, and an anti-glaucoma compound. The invention also includes adding pvp-i to an ophthalmic composition in order to preserve the composition, wherein the pvp-i is added at a concentration sufficient to preserve the composition..
09/19/13
20130243798
Peptides for vaccine against birch allergy
The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.. .
09/12/13
20130236473
Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
The compound that inhibits expression of the function of a protein belonging to erbb1 pathway provided as means for achieving the object is capable of suppressing the activity of il-6 amplifier, thereby reducing production of inflammatory cytokine such as il-6. Therefore, the compound that inhibits the function of a protein belonging to erbb1 pathway can be used as an active ingredient of the therapeutic agent or the prophylactic agent for at least one disease or symptom selected from the group consisting of autoimmune diseases, inflammatory diseases, allergic diseases, and symptoms accompanying organ transplants..
09/05/13
20130230551
Allergy inhibitor compositions and kits and methods of using the same
Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed..
08/22/13
20130216574
Kit providing multiple unmet therapeutic effects
The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus.
08/08/13
20130203182
Method for decision support in allergy diagnosis
A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting a plurality of allergens to be tested for in the sample, c) determining for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed..
08/01/13
20130197221
Benzimidazole derivatives as pi3 kinase inhibitors
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
08/01/13
20130196990
Benzimidazole derivatives as pi3 kinase inhibitors
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
08/01/13
20130195902
Recombinant allergen
Dander from the domestic cat (felis domesticus) is one of the most common causes of ige mediated allergy. The present invention relates to a recombinant folded fel d 1 with molecular and biological properties similar to the natural counterpart and specifically a synthetic gene coding for a direct fusion of fel d 1 chain 2 n-terminally to chain 1.
07/25/13
20130191149
Latex detection and warning system and method
Provided is an apparatus that stores a formulary. The apparatus includes a memory device that stores the formulary, the formulary comprising a plurality of drug entries.
07/25/13
20130190496
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
And pharmaceutically acceptable salts thereof, wherein x1, x2, x3, x4, x5, x6, x7, r1, and q1 are defined herein, inhibit the igf-1r enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.. .
07/18/13
20130183377
Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, aids, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent hla restriction in humans and livestock.
07/11/13
20130177575
Novel therapeutic target and diagnostic marker for asthma and related conditions
Cd48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. Cd48 is thus presented as a target molecule in the treatment of said conditions.
07/11/13
20130177557
Vista regulatory t cell mediator protein, vista binding agents and use thereof
The present invention relates to a novel regulatory t cell protein. This protein, designated pd-l3 or vista resembles members of the pd-l1 family, identified a novel and structurally-distinct, ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the b7 family ligand pd-l1.


Popular terms: [SEARCH]

Allergy topics: Autoimmune, Prophylactic, Ophthalmic, Autoimmune Disorder, Immune Disorder, Dermatitis, Staurosporin, Aspergillosis, Angioedema, Allergic Rhinitis, Food Allergy, Therapeutical, Bronchopulmonary, Staurosporine, Sudden Infant Death

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Allergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2432

3125

0 - 1 - 72